Mehta Asmita Anilkumar, Jose Wesley M, Pavithran Kicheelath, Triavadi Ganesan S
Department of Pulmonary Medicine, Cancer Institute and Institute of Molecular Medicine, Amrita Institute of Medical Sciences, AIMS Ponekkara P.O. Kochi, Kerala, India.
Indian J Palliat Care. 2013 Jan;19(1):48-53. doi: 10.4103/0973-1075.110237.
Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor, represents a new treatment option for patients with advanced non-small-cell lung cancer (NSCLC). We analyzed the data of patients who received Gefitinib for NSCLC in a tertiary care center in South India.
Sixty-three patients with advanced NSCLC who had received Gefitinib either after failure of conventional chemotherapy or were previously not treated as they were unfit or unwilling for conventional treatment were included in the analysis.
The median follow-up for the cohort was 311 days (range 11-1544 days). Median time to progression was 161 (range 9-883) days. Complete and partial remission was seen in 1 (2%) and 6 (9%) patients, respectively, with overall response rate of 11%. Twenty-four (38%) patients had stable disease. Gefitinib was well tolerated with no significant side effects.
Gefitinib shows anti-tumor activity in pretreated or previously untreated patients with advanced NSCLC. It has a favorable toxicity profile and is well tolerated. Gefitinib should be considered as a viable therapy in patients with NSCLC.
吉非替尼是一种表皮生长因子受体酪氨酸激酶抑制剂，为晚期非小细胞肺癌（NSCLC）患者提供了一种新的治疗选择。我们分析了印度南部一家三级医疗中心接受吉非替尼治疗的NSCLC患者的数据。
分析纳入了63例晚期NSCLC患者，这些患者要么在传统化疗失败后接受了吉非替尼治疗，要么因不适合或不愿意接受传统治疗而未接受过治疗。
该队列的中位随访时间为311天（范围11 - 1544天）。中位疾病进展时间为161天（范围9 - 883天）。分别有1例（2%）和6例（9%）患者达到完全缓解和部分缓解，总缓解率为11%。24例（38%）患者病情稳定。吉非替尼耐受性良好，无明显副作用。
吉非替尼在经治或初治的晚期NSCLC患者中显示出抗肿瘤活性。它具有良好的毒性特征且耐受性良好。吉非替尼应被视为NSCLC患者的一种可行治疗方法。
